Cel-Sci and Ergomed Sign Co-Development and Profit Sharing Agreement for Multikine in HIV/HPV Co-Infected Men and Women with Peri-Anal Warts
CEL-SCI Corporation announced that it has signed a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. for CEL-SCI’s investigational immunotherapy drug Multikine (“Leucocyte Interleukin Inj.”) in HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI has also recently entered a Cooperative Research and Development Agreement (CRADA) for this disease indication with the US Naval Medical Center, San Diego.
CEL-SCI Corporation Holds Clinical Investigator Meeting for 56 European Centers Participating in Ongoing Phase III Cancer Trial with Multikine
CEL-SCI Corporation announced today it has held the Investigator Meeting for the European clinical investigators participating in the ongoing Phase III clinical trial of CEL-SCI’s investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Inj.). The meeting had 108 participants from 56 clinical centers that are or will be participating in the Multikine Phase III clinical trial for head and neck cancer. These clinical centers come from 13 European countries. The Investigator Meeting for the clinical centers in the United States and Canada is scheduled for November 2013. A total of approximately 880 patients are expected to be enrolled in this international Phase III study.
The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. About 6% of all cancers are head and neck cancer with an estimated 650,000 new cases globally and about 150,000 in the U.S. and Europe. The objective of the study is to demonstrate a statistically significant 10% improvement in overall survival of enrolled patients who are treated with the investigational therapy Multikine plus Standard of Care (SOC) vs. subjects who are treated with SOC only. Multikine is intended to create an anti-tumor immune response to reduce local / regional tumor recurrence and thereby increase the survival of these patients.
Cel-Sci and Ergomed Sign Co-Development and Profit Sharing Agreement for Multikine in HIV/HPV Co-Infected Women with Cervical Dysplasia
CEL-SCI Corporation announced that it has signed a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. for CEL-SCI’s investigational immunotherapy drug Multikine (“Leucocyte Interleukin Inj.”) in HIV/HPV co-infected women with cervical dysplasia. Human Papilloma Virus (HPV) is the most common sexually transmitted disease. HPV is a significant health problem in the HIV infected population as individuals are living longer as a result of greatly improved HIV medications. People living with HIV and others with compromised immunity are more at risk for HPV-related complications. Persistent HPV infection can also be a precursor to cervical cancer.